Table 1.

Characteristics of patients in constituent trials.

Study Name	Authors, Year	Treatment Comparison	Median OS (months)	Phase	Line of therapy	No. of Patients	Never-Smoker (%)	Non-Squamous (%)	EGFR Mutation (%)	KRAS Mutation (%)	Age < 65 years (%)	Women (%)	ECOG PS 0 (%)	Central Nervous System Metastasis (%)
CheckMate 017	Brahmer et al, 2015	Nivomulab v Docetaxel	9.2 v 6.0	3	Second	272	6	0	N/A	N/A	56	24	24	6
CheckMate 057	Borghaei et al, 2015	Nivomulab v Docetaxel	12.2 v 9.4	3	Second/ third	582	20	100	14	11	58	93	31	12
CheckMate 026	Carbone et al, 2017	Nivomulab v Platinum-based chemotherapy	13.7 v 13.8	3	First	541	11	76	0	N/A	52	39	33	13
KEYNOTE-010	Herbst et al, 2016	Pembrolizumab v Docetaxel	10.4 v 12.7 v 8.5	2/3	Second or later	1034	18.4	70	8	N/A	58	39	34	15
KEYNOTE-024	Reck et al, 2016	Pembrolizumab v Platinum-based chemotherapy	Not Reached	3	First	305	7.9	81.6	0	N/A	46	39	35	9
POPLAR	Fehrenbacher et al, 2016	Atezolizumab v docetaxel	12.6 v 9.7	2	Second/ third	287	19.5	66	6.6	9.4	N/A	41	32	N/A
OAK	Rittmeyer et al, 2016	Atezolizumab v docetaxel	13.8 v 9.6	3	Second/ third	850	18	74	10	7	53	39	37	10